Table 1 Results of clinical trials using MSCs to treat GVHD

No.1

27.8y (1–65)

SR grade II–IV GVHD

3 (children: 2–7 adults: 2–11)

1.5 (0.8–3.1)

OR:67.5 CR:27.5

N/A

1y:50 2y:38.6 median survival time:1.1y

2.8y

Introna et al. [54]

No.2

44.9y (1.3–68.9)

SR grade II–IV aGVHD

3 (1–4)

1.8 (0.9–2.5)

CR:25

N/A

1y:44

150d

Te Boome et al. [71]

No.7

21–66y

refractory acute or chronic GVHD

aGVHD:1–4 cGVHD:1–3

0.2–2.9

N/A

exact time unknown:aGVHD:OR:70 CR:10 cGVHD:OR:50 CR:12.5

N/A

N/A

Pérez-Simon et al. [55]

No.12

 ≤ 18y

N/A

N/A

N/A

N/A

N/A

N/A

N/A

https://clinicaltrials.gov/ct2/show/results/NCT02379442?term=02379442&draw=2&rank=1

No.14

58y (5–69)

grade II–IV SR aGVHD

1/2

1–2 or 3–4

OR:40.6 CR:21.9 (30 d)

90d:OR:46.9 CR:31.2

90d:30.3 1y:18.2

1y

Servais et al. [96]

No.23

50y (20–61)

moderate to severe refactory cGVHD

6–9

2

N/A

time points varies from different patients:OR:54.5

N/A

76m

Boberg et al. [75]

No.27

7y (0–17)

grade II–IV SR aGVHD(excluding skin-only grade II)

8

2

OR:70.4 CR:29.6

56d:OR:59.3 CR:31.5 100d:OR:70.4 CR:44.4

100d:74.1 180d:68.5

180d

Kurtzberg et al. [37]

No.32

group A:51y (24–60) group B:46y (36–60)

moderate or severe cGVHD

1

group A:1 group B:3

N/A

20w:OR:71.4 CR:35.7 42w:OR:71.4 CR:42.9 56w:OR:71.4 CR:57.1

56w:71.4 median survival time:45.3w

56w

Jurado et al. [102] 

No.35

18–70y

grade II–IV SR aGVHD

2

cohort A:1 cohort B:2

cohort A:OR:62.5 CR:12.5 cohort B:OR:85.7 CR:57.1 total:OR:77.3 CR:33.3

100d:cohort A:OR:87.5 CR:50 cohort B:OR:85.7 CR:57.1 total:OR:86.7 CR:53.3

100d:cohort A:87.5 cohort B:85.7 total:86.7

100d

Bloor et al. [39]

No.42

6 m–70y

SR grade II–IV aGVHD

8 (+ 4)

2

OR:remestemcel-L group:58 placebo group:54 p = 0.59

N/A

180d:remestemcel-L group:34 placebo group:42

180d

Kebriaei et al. [64]

No.42

N/A

SR aGVHD

8 (+ 4)

2

N/A

100d:OR:remestemcel-L group:82 placebo:73 p = 0.12

N/A

N/A

Martin et al. [88]

No.43

57.5y (35–73)

de novo high risk or SR grade I–IV aGVHD

2

low dose group:2 high dose group:10

OR:70 CR:40

N/A

100d:90 180d:60

N/A

Soder et al. [103]

No.44

52y (34–67)

grade II–IV aGVHD

2

low dose group:2 high dose group:8

low dose group:OR:87.5 CR:87.5 high dose group:OR:100 CR:66.7 total:OR:94 CR:77

N/A

90d:71.0

90d

Kebriaei et al. [87]

No.45

36y (21–52)

refractory acute and chronic GVHD

1

1.0

N/A

1w:OR:40

5w:90.9

5w

Yi et al. [58]

No.50

9.6y (0.3–18.2)

grade II–IV SR aGVHD

11 (1–24)

2

OR:65.1 CR:14.1

100d:OR:51.5 CR:32.8

100d:66.9

100d

Kurtzberg et al. [37]

No.50

7.8y (0.2–17.5)

grade II–IV SR aGVHD

10 (1–20)

2

OR:61.3

100d:OR:77

100d:57.3

100d

Kurtzberg et al. [67]

No.53

group1:54.5y (0.9–65.6) group2:48.9y (1.6–72.4)

grade II–IV aGVHD

group1:1 (1–5) group2:2 (1–6) p = 0.002

group1:2.0 (0.9–2.8) group2:1.2 (0.9–2.9) p < 0.001

group1:OR:58.8 CR:29.4 group2:OR:100 CR:52.4 p = 0.013 group1 SR patients:OR:46 group2 SR patients:OR:100

N/A

1y:group1:47 group2:76 p = 0.016 group1 SR patients:31 group2 SR patients:73 p = 0.02

N/A

Ringden et al. [56]

No.53

49y (1.6–72)

grade II–IV aGVHD

2 (1–6)

1.2 (0.9–2.9)

OR:100 CR:52.4

56d:OR:95

1y:81 2y:67 4y:57 SR patients:4y:55

4y

Sadeghi et al. [104]

No.64

52y (4–62)

SR grade II–III aGVHD

8 (5–12)

2

OR:93 CR:57

24w:OR:93 CR:85.7

24w:78.6 96w:57.1

96w

Muroi et al. [34]

No.65

33y (5–66)

SR grade III–IV aGVHD

4–12

2

OR:60 CR:24

12w:OR:60 CR:52 24w:OR:60 CR:48 36w:OR:52 CR:44

52w:48

52w

Muroi et al. [35]

No.66

41.5y (17–68)

severe SR cGVHD

4

1

N/A

8w:PR:100

exact time unknown:90

N/A

Kim et al. [28]

No.69

aGVHD:21–61y cGVHD:31–53y

grade II–IV SR aGVHD;SR cGVHD

aGVHD:2–19 cGVHD:2–11

1.7–2.3

N/A

exact time unknown:aGVHD:OR:92 CR:58 cGVHD:OR:57 CR:29

aGVHD:3y:55 cGVHD:median survival time:8m

N/A

Herrmann et al [74]